57 filings
8-K
LOXO
Loxo Oncology, Inc.
15 Feb 19
Completion of Acquisition or Disposition of Assets
4:41pm
8-K
LOXO
Loxo Oncology, Inc.
7 Jan 19
Entry into a Material Definitive Agreement
7:14am
8-K
LOXO
Loxo Oncology, Inc.
2 Jan 19
Departure of Directors or Certain Officers
4:30pm
8-K
LOXO
Loxo Oncology, Inc.
6 Dec 18
Regulation FD Disclosure
4:30pm
8-K
LOXO
Loxo Oncology, Inc.
27 Nov 18
FDA Approves VitrakviĀ®Ā (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion1,2
6:01am
8-K
ikot kkrqmfwnml7iwyf
8 Nov 18
Loxo Oncology Reports Third Quarter 2018 Financial Results
6:45am
8-K
c3swnhkhu68svl9v
17 Sep 18
Other Events
12:00am
8-K
5wmv8mcqt f5evkbp
9 Aug 18
Loxo Oncology Reports Second Quarter 2018 Financial Results
6:46am
8-K
1d64kv
14 Jun 18
Departure of Directors or Certain Officers
12:00am
8-K
4u2w0sh
4 Jun 18
Regulation FD Disclosure
12:00am
8-K
ixnyyhg qqgmip
8 May 18
Loxo Oncology Reports First Quarter 2018 Financial Results
6:45am
8-K
gj6obm7kxw zs7htfnm
1 Mar 18
Loxo Oncology Reports Fourth Quarter and Year-End 2017 Financial Results
12:00am
8-K
bk2bi
21 Feb 18
Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine
12:00am
8-K
ouw9qx5301 lhsce
8 Jan 18
Regulation FD Disclosure
12:00am
8-K
ntsmfjfxnz m8
27 Dec 17
Departure of Directors or Certain Officers
12:00am
8-K
15ng5
4 Dec 17
Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion Cancers
12:00am
8-K
bgpdsdehu3
21 Nov 17
Entry into a Material Definitive Agreement
12:00am
8-K
puuusa 6dq8ttytqsvu
14 Nov 17
Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195
12:00am
8-K
jevio c9jq72
2 Nov 17
Results of Operations and Financial Condition
12:00am
8-K
ci4nbwhou9tiy
18 Oct 17
Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset
12:00am